Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179621
Status:
COMPLETED
Last Update Posted:
2011-04-14
First Post:
2005-09-10
Brief Title:
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q31 Abnormality
Sponsor:
Celgene Corporation
Organization:
Celgene
Organization Data
Organization:
Celgene
Class:
INDUSTRY
Study ID:
CC-5013-MDS-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celgene Corporation
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Jay Backstrom MD Vice President Clinical Development MDS
Old Organization:
Celgene Corporation
Collaborators
| Name | Class |
|---|---|
| ICON Clinical Research | INDUSTRY |